The-137G/C Polymorphism in Interleukin-18 Gene Promoter Contributes to Chronic Lymphocytic and Chronic Myelogenous Leukemia Risk in Turkish Patients

Yalcin S., MUTLU P., Cetin T., Sarper M., Ozgur G., Avcu F.

TURKISH JOURNAL OF HEMATOLOGY, vol.32, no.4, pp.311-316, 2015 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 32 Issue: 4
  • Publication Date: 2015
  • Doi Number: 10.4274/tjh.2014.0126
  • Journal Indexes: Science Citation Index Expanded, Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.311-316
  • Keywords: 1L-18, Chronic lymphocytic leukemia, Chronic myelogenous leukemia, Single nucleotide polymorphisms, NORTH INDIAN POPULATION, PROINFLAMMATORY CYTOKINE, PROSTATE-CANCER, IL-18, EXPRESSION, CARCINOMA, RECEPTOR, CELLS, ASSOCIATION, SUSCEPTIBILITY


Objective: Interleuldn-18 (IL-18) is a cytokine that belongs to the IL-1 superfamily and is secreted by various immune and nonimmune cells. Evidence has shown that 1L-18 has both anticancer and procancer effects. The aim of this study was to evaluate the relationship between IL-18 gene polymorphisms and susceptibility to chronic lymphocytic leukemias (CLL) and chronic myelogenous leukemias (CML) in Turkish patients.